OBJECTIVE: Evaluate persistence with treatment, healthcare costs, and utilization in stably enrolled Aetna Behavioral Health members receiving extended-release naltrexone (XR-NTX) for alcohol use dependence compared with oral medications and psychosocial therapy only. STUDY DESIGN: Historical cohort study. METHODS: Aetna beneficiaries with stable enrollment (at least 6 months before and after index treatment) who initiated pharmacotherapy with XR-NTX (n = 211), disulfiram (n = 1043), oral naltrexone (n = 1408), acamprosate (n = 2479), or psychosocial therapy only (n = 6374) for alcohol use disorders between January 1, 2007, and December 31, 2008, were extracted and deidentified from Aetna's nationwide claims and utilization database. Survival analysis compared persistence with XR-NTX versus oral pharmacotherapies. Difference-in-differences analysis compared healthcare costs and utilization among patients receiving XR-NTX versus oral pharmacotherapies and psychosocial therapy only. Multivariate analyses controlled for demographics. RESULTS: Patients taking acamprosate and disulfiram were more likely to discontinue treatment than patients taking naltrexone, and patients given oral naltrexone were more likely to discontinue treatment than those given XR-NTX. Outpatient behavioral health treatment visits increased in all study groups. Nonpharmacy healthcare costs and utilization of inpatient and emergency services decreased in the XR-NTX group relative to other study groups. CONCLUSION: Patients receiving XR-NTX persisted with treatment longer than patients receiving oral alcohol use-disorder medications or psychosocial therapy only, and had decreased inpatient and emergency healthcare costs and utilization compared with those receiving other medications.
OBJECTIVE: Evaluate persistence with treatment, healthcare costs, and utilization in stably enrolled Aetna Behavioral Health members receiving extended-release naltrexone (XR-NTX) for alcohol use dependence compared with oral medications and psychosocial therapy only. STUDY DESIGN: Historical cohort study. METHODS:Aetna beneficiaries with stable enrollment (at least 6 months before and after index treatment) who initiated pharmacotherapy with XR-NTX (n = 211), disulfiram (n = 1043), oral naltrexone (n = 1408), acamprosate (n = 2479), or psychosocial therapy only (n = 6374) for alcohol use disorders between January 1, 2007, and December 31, 2008, were extracted and deidentified from Aetna's nationwide claims and utilization database. Survival analysis compared persistence with XR-NTX versus oral pharmacotherapies. Difference-in-differences analysis compared healthcare costs and utilization among patients receiving XR-NTX versus oral pharmacotherapies and psychosocial therapy only. Multivariate analyses controlled for demographics. RESULTS:Patients taking acamprosate and disulfiram were more likely to discontinue treatment than patients taking naltrexone, and patients given oral naltrexone were more likely to discontinue treatment than those given XR-NTX. Outpatient behavioral health treatment visits increased in all study groups. Nonpharmacy healthcare costs and utilization of inpatient and emergency services decreased in the XR-NTX group relative to other study groups. CONCLUSION:Patients receiving XR-NTX persisted with treatment longer than patients receiving oral alcohol use-disorder medications or psychosocial therapy only, and had decreased inpatient and emergency healthcare costs and utilization compared with those receiving other medications.
Authors: Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler Journal: J Clin Psychopharmacol Date: 2007-10 Impact factor: 3.153
Authors: Joshua D Lee; Ellie Grossman; Danae DiRocco; Andrea Truncali; Kathleen Hanley; David Stevens; John Rotrosen; Marc N Gourevitch Journal: J Subst Abuse Treat Date: 2010-04-02
Authors: Henry R Kranzler; Leslie B Montejano; Judith J Stephenson; Shaohung Wang; David R Gastfriend Journal: Alcohol Clin Exp Res Date: 2010-04-05 Impact factor: 3.455
Authors: Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley Journal: Alcohol Clin Exp Res Date: 2008-11-25 Impact factor: 3.455
Authors: Sarah E Wakeman; Nancy A Rigotti; Yuchiao Chang; Grace E Herman; Ann Erwin; Susan Regan; Joshua P Metlay Journal: J Gen Intern Med Date: 2019-01-10 Impact factor: 5.128
Authors: Maria A Sullivan; Adam Bisaga; Andrew Glass; Kaitlyn Mishlen; Martina Pavlicova; Kenneth M Carpenter; John J Mariani; Frances R Levin; Edward V Nunes Journal: Drug Alcohol Depend Date: 2014-12-09 Impact factor: 4.492
Authors: Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen Journal: J Subst Abuse Treat Date: 2013-03-13